Clinical Trial ResultsUnicycive announced positive results from the safety and tolerability pivotal trial for phosphate binder, oxylanthanum carbonate.
Market OpportunityGiven the improvements to pill burden and potentially even efficacy based on the recent pivotal study, there is a multi-hundred million dollar opportunity for Unicycive that should flow through to shareholders in the form of a planned dividend for 75% of operating cash flow.
Regulatory ProgressUnicycive announced it has submitted the NDA for Oxylanthanum Carbonate (OLC) to treat hyperphospatemia in chronic kidney disease (CKD) patients on dialysis.